The dynamics of prostate specific antigen during watchful waiting of prostate carcinoma
Open Access
- 15 March 2002
- Vol. 94 (6) , 1692-1698
- https://doi.org/10.1002/cncr.10443
Abstract
BACKGROUND For the moment, there is uncertainty about the usefulness of early treatment of localized prostate carcinoma, uncertainty about whether some patients with early cancer can be managed expectantly, and uncertainty about how such patients might be recognized. METHODS The authors studied serial values of prostate specific antigen (PSA) in 94 Japanese men with diagnosed prostate carcinoma and who were managed by watchful waiting. Their median follow-up duration was 32 months (range, 1.6–118). The authors used a log-linear model to fit the values of PSA over time, and then they used the Cox survival model to relate the intercept (PSA amplitude) and slope (relative velocity) to observed local or systemic outcomes that were independent of PSA. RESULTS The authors found that the log-linear model fit the serial values of PSA during watchful waiting very well. Prostate specific antigen amplitude related significantly to T classification (P = 0.0006), but not to grade (P > 0.2), and the relative velocity related significantly to both T classification (P = 0.009) and to grade (P = 0.02). Although the T classification, histologic grade, and log(PSA) at diagnosis were associated significantly with time to outcome, the combination of amplitude and relative velocity provided more information. These 2 PSA parameters resulted in a higher model likelihood ratio, and their individual P values in the Cox model were 0.0005 and 0.005, respectively. With these two in the Cox model, T classification, grade, log(PSA), and PSA doubling time provided no further significant information. CONCLUSIONS A log-linear model seems to fit serial measurements of PSA during watchful waiting, and preliminary results suggest that both the amplitude and the relative velocity relate closely to clinical outcomes. Cancer 2002;94:1692–8. © 2002 American Cancer Society. DOI 10.1002/cncr.10443Keywords
This publication has 24 references indexed in Scilit:
- Outcome research after radical retropubic prostatectomy for prostate cancerJNCI Journal of the National Cancer Institute, 1998
- EVALUATION OF CHANGES IN PROSTATE SPECIFIC ANTIGEN IN CLINICALLY LOCALIZED PROSTATE CANCER MANAGED WITHOUT INITIAL THERAPYJournal of Urology, 1998
- Deferred treatment of clinically localized low-grade prostate cancer: Actual 10-year and projected 15-year follow-up of the karolinska seriesUrology, 1997
- Serial Prostate Specific Antigen Measurements and Progression in Untreated Confined (Stages T0 to 3NxM0, Grades 1 to 3) Carcinoma of ProstateJournal of Urology, 1995
- Results of Conservative Management of Clinically Localized Prostate CancerNew England Journal of Medicine, 1994
- Linear regressive analysis using prostate-specific antigen doubling time for predicting tumor biology and clinical outcome in prostate cancerCancer, 1993
- Observations on the doubling time of prostate cancer.The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volumeCancer, 1993